Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium.
The tripeptide amide glycyl-prolyl-glycinamide (GPG-amide) is a new antiretroviral drug candidate, but its absorption mechanism is unknown. In this investigation, the transport and metabolism of GPG-amide were studied in a model of the human intestinal epithelium, Caco-2 cell monolayers. The results show that when the tripeptide amide came into contact with the apical enterocyte membrane, it was degraded by CD26 (dipeptidyl peptidase IV) to glycylproline and the antiretrovirally active metabolite glycinamide. Glycinamide retained antiretroviral activity in vitro after transport through the Caco-2 cell monolayers. The transport of glycinamide across Caco-2 cell monolayers occurred via passive diffusion with an apparent permeability coefficient of about 2 x 10(-6) cm s(-1), which suggests that it is absorbed by the oral route in sufficient amounts to be considered for oral administration. In conclusion, the tripeptide GPG-amide acts as a prodrug that is activated by CD26 to release the orally active antiretroviral compound glycinamide.
Hubatsch
Ina
I
Department of Pharmacy, Biomedical Center, Uppsala University, S-75123 Uppsala, Sweden.
Lazorova
Lucia
L
Vahlne
Anders
A
Artursson
Per
P
D000284:Administration, Oral; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001692:Biological Transport; D001711:Biotransformation; D018938:Caco-2 Cells; D018819:Dipeptidyl Peptidase 4 / Q000502:physiology*; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000378:metabolism*; D009842:Oligopeptides / Q000493:pharmacokinetics*
D000998:Antiviral Agents; D009842:Oligopeptides; C018556:glycine amide; C425285:glycylprolylglycine amide; D018819:Dipeptidyl Peptidase 4; D005998:Glycine
Clin Microbiol Infect. 2003 Mar;9(3):186-93
12667250
Antimicrob Agents Chemother. 2005 Jan;49(1):40-4
15616273
Antiviral Res. 2004 Feb;61(2):119-24
14670585
Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59
15183349
Ciba Found Symp. 1977;(50):61-77
244391
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S41-50
11033426
J Hum Virol. 2001 Jan-Feb;4(1):1-7
11213928
J Hum Virol. 2001 Jan-Feb;4(1):8-15
11213934
J Med Chem. 2001 Jun 7;44(12):1927-37
11384238
AAPS PharmSci. 2001;3(1):E9
11741260
Methods Mol Biol. 2002;188:233-72
11987548
Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605
12384371
Pharmacol Toxicol. 2002 Jun;90(6):285-96
12403049
J Med Chem. 2003 Feb 13;46(4):558-70
12570377
Life Sci. 1984 May 21;34(21):1985-98
6727550
Cell. 1990 Feb 9;60(3):429-37
2302734
Pharm Res. 1991 Feb;8(2):210-6
2023869
Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
1673839
Biochem J. 1992 Jun 1;284 ( Pt 2):595-601
1318037
Pharm Res. 1993 Jan;10(1):113-8
8430047
J Physiol. 1998 Mar 15;507 ( Pt 3):697-706
9508831
Pharm Res. 2003 Mar;20(3):397-405
12669959